Get the Stockscreener App
0.3661
7.68%
0.0261
After Hours:
.37
0.0039
+1.07%
Aspire Biopharma Holdings Inc stock is traded at $0.3661, with a volume of 158.71K.
It is up +7.68% in the last 24 hours and down -18.85% over the past month.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
See More
Previous Close:
$0.34
Open:
$0.355
24h Volume:
158.71K
Relative Volume:
0.36
Market Cap:
$22.15M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-19.18%
1M Performance:
-18.85%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.341
$0.38
1-Week Range:
$0.3298
$0.51
52-Week Range:
$0.3298
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Name
Aspire Biopharma Holdings Inc
Sector
Industry
Phone
561-704-8527
Address
194 CANDELARO DRIVE, #233, HUMACAO
Compare ASBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.3661 | 22.15M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Aspire Biopharma Holdings Inc Stock (ASBP) Latest News
Aspire Biopharma Holdings Inc (ASBP) Stock: A Comprehensive 52-Week Review - investchronicle.com
Was anything negative for Aspire Biopharma Holdings Inc (ASBP) stock last session? - uspostnews.com
Post-Trade Analysis: Aspire Biopharma Holdings Inc (ASBP) Slides -15.33, Closing at 0.36 - DWinneX
Aspire Biopharma Settles with Lenders, Extends Loan Maturities By Investing.com - Investing.com Nigeria
Aspire Biopharma Settles with Lenders, Extends Loan Maturities - Investing.com Australia
Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - The Joplin Globe
Press Release Distribution & PR Platform - ACCESS Newswire
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17 - Weatherford Democrat
Aspire Biopharma starts production of pre-workout supplement By Investing.com - Investing.com South Africa
Aspire Biopharma starts production of pre-workout supplement - Investing.com Australia
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement - standard-journal.com
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Weatherford Democrat
Aspire Biopharma Holdings Inc. (ASBP) reports earnings - Quartz
Aspire Biopharma Holdings, Inc. SEC 10-K Report - TradingView
ASBP stock touches 52-week low at $0.51 amid sharp annual decline - Investing.com Canada
ASBP stock touches 52-week low at $0.51 amid sharp annual decline By Investing.com - Investing.com South Africa
There is no way Aspire Biopharma Holdings Inc (ASBP) can keep these numbers up - SETE News
Sector Update: Health Care - MarketScreener
Aspire Biopharma Says Glatt Air Produces First Batch of Oral Mucosal Form of Aspirin -March 20, 2025 at 10:11 am EDT - Marketscreener.com
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin - standard-journal.com
Aspire Biopharma advances patent applications for drug delivery tech By Investing.com - Investing.com Australia
Aspire Biopharma advances patent applications for drug delivery tech - Investing.com India
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform - ACCESS Newswire
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga
An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation - The Kingston Whig-Standard
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement - wicz.com
Dykema Advises PowerUp Acquisition Corp. in Aspire Biopharma’s Nasdaq Listing - Dykema
Aspire Biopharma advances to phase 1 clinical trial for aspirin product - Investing.com India
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin - Corsicana Daily Sun
PowerUp Acquisition Corp. Approves Merger with Aspire Biopharma - MSN
Dow Tumbles Over 700 Points; US Services PMI Falls In February - Benzinga
Aspire Biopharma Strengthens Financial Position with Debentures - TipRanks
Stock market news: Aspire Biopharma Holdings -51.46%, bluebird bio -39.20% among biggest losers during midday trading - Business Upturn
Stock market news: MicroAlgo skyrocketed by 480.87% whereas Mobile-health Network plunged by 42.65% during midday trading - Business Upturn
Aspire Biopharma Hldgs Stock Price, Quotes and Forecasts | NASDAQ:ASBP - Benzinga
POWERUP ACQUISITION CORP. Submission of Matters to a Vote of Security Holders (form 8-K/A) - Marketscreener.com
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement - WICZ
Aspire Biopharma Holdings Inc Stock (ASBP) Financials Data
There is no financial data for Aspire Biopharma Holdings Inc (ASBP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):